Direct link found between opioid use and socioeconomic status.

A longitudinal cohort study identifies 4 distinct trajectories.

Frequent use remains high with advanced age, multiple comorbidities, and polypharmacy.

Results from a meta-analysis.

Prolonged treatment, higher doses of urate-lowering therapy carry higher T2D risk.

Rates highest among younger women with spinal OA.

Although clinically effective, the cost may not be justifiable.

Meta-analysis shows >2-fold higher risk with current use of short-acting formulations.

Adolescent girls take longest to recover.

Detailed safety analysis based on phase 3 trial that led to FDA approval.

61% of cases occurred in children aged 5 years and younger; most were unintentional.

Close monitoring will be required to avert an opioid crisis.

3 phase 3 trials of patients with episodic or chronic migraine.

It works as well as intranasal fentanyl, but with more minor adverse events.